Volume 2, Issue 2, March 2016, Page: 26-30
Effects of β-Glucan on Natural Killer Cells in Patients Recovering from Cancer Treatment: Clinical Trial
Josef Richter, Health Institute (Zdravotni ustav se sidlem) of Usti nad Labem, Usti nad Labem, Czech Republic
Vlastimil Kral, Health Institute (Zdravotni ustav se sidlem) of Usti nad Labem, Usti nad Labem, Czech Republic
Jitka Pohorska, Health Institute (Zdravotni ustav se sidlem) of Usti nad Labem, Usti nad Labem, Czech Republic
Lucie Rajnohova Dobiasova, Health Institute (Zdravotni ustav se sidlem) of Usti nad Labem, Usti nad Labem, Czech Republic
Vaclav Vetvicka, University of Louisville, Department of Pathology, Louisville, KY, USA
Received: Mar. 8, 2016;       Accepted: Mar. 11, 2016;       Published: Apr. 25, 2016
DOI: 10.11648/j.ijcems.20160202.12      View  3891      Downloads  121
Glucan is the most studied immunomodulator. Among its properties, effects on cancer are the closest to clinical use. In our study, we evaluated the effects of short-term supplementation with glucan on NK cells in patients recovering from different types of cancer treatment. NK cells represent a distinct sub-population of lymphocytes endowed with the capacity to kill tumor cells without prior sensitization and form one of the most important defense mechanisms against cancer. To measure the numbers of NK cells, flow cytometer measuring four colors was used. Using a double-blind, placebo-controlled clinical trial, we found that adding glucan to the diet strongly increased the number of NK cells in blood.
Cancer, Glucan, NK Cells, Immunity, Lymphocytes
To cite this article
Josef Richter, Vlastimil Kral, Jitka Pohorska, Lucie Rajnohova Dobiasova, Vaclav Vetvicka, Effects of β-Glucan on Natural Killer Cells in Patients Recovering from Cancer Treatment: Clinical Trial, International Journal of Clinical and Experimental Medical Sciences. Vol. 2, No. 2, 2016, pp. 26-30. doi: 10.11648/j.ijcems.20160202.12
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Katchar K, Frouin EE, Steere AC. Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Res. Therapy 2013; 15: 1–11.
Lanier LL. Shades of grey- the blurring view of innate and adoptive immunity. Nat Rev Immunol. 2013; 13: 73–74.
Coppola A, Arriga R, Lauro D, Lauro D, del Principe MI, Buccisano F, Maurillo L, Palomba P, Venditti A, Sconocchia G. NK cell inflammation in the clinical outcome of colorectal carcinoma. Frontiers Med. 2015; 2: 1–6.
Yoon SR, Kim T, Choi I. Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med. 2015; 47: 1–11.
Silverman MN, Heim CM, Nater UM, Marques AH, Stenberg EM. Neuroendocrine and immune contributors to fatigue. PM&R: J Injury, Funct Rehab. 2010; 2: 338–346.
Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Neurobehavioral effects of interferon- in cancer patients: Phenomenology and Paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-652.
Richter J, Kral V, Stiborova I, Rajnohova D, Vetvicka V. Anti-inflammatory effects of β-glucan in cancer related fatigue. J Nutr Health Sci. 2015; 2: 1–7.
Goodwin PJ, Leszcz M, Ennis M, Koopmans J, Vincent L, Guther H, Drysdale E, Hundleby M, Chochinov HM, Navarro M, Speca M, Masterson J, Dohan L, Sela R, Warren B, Paterson A, Pritchard KI, Arnold A, Doll R, O’Reilly SE, Quirt G, Hood N, Hunter J. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001; 345: 1719-1726.
Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O’Keene V. Hypothalamo-pituitary-adrenal exis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab. 2001; 86: 3545-3554.
Natelson BH, Haghighi MH, Ponzio NM. Evidence for the presence of immune dysfunction in chronic fatique syndrome. Clin Diagn Lab Immunol. 2002; 9: 747-752.
Nijs J, Nees A, Paul L, De Kooning M, Ickmans K, Meeus M, Van Oosterwijck J. Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Res. 2014; 20: 94-116.
Jones RJ, Armstrong SA. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant. 2008; 14: 12-16.
Weitberg AB. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J Exp Clin Canc Res. 2008; 27: 1–4.
Hofer M, Pospisil M. Modulation of animal and human hematopoiesis by β-glucans: A review. Molecules 2011; 16: 7969–7979.
Patchen ML, D’Alesandro MM, Brook I, Blakely WF, MacVittie TJ. Glucan: Mechanisms involved in its “radioprotective” effects. J Leukocyte Biol. 1987; 42: 95-105.
Lin H, Cheung SWY, Nesin M, Casselith BR, Cunningham-Rundles S. Enhancement of umbilical cord blood cell hematopoiesis by Maitake beta-glucan is mediated by granulocyte colony-stimulating factor production. Clin Vaccine Immunol. 2007; 14: 21-27.
Pillai TG, Maurya DK, Salvi VP, Janardhanan KK, Nair CKK. Fungal beta glucan proteus radiation induced DNA damage in human lymphocytes. Ann Transl Med. 2014; 2: 1–7.
Sima P, Vannucci L, Vetvicka V. Effects of glucan on bone marrow. Ann Transl Med. 2014; 2: doi: 10.3978/j.issn.2305-5839.2014.01.06
Patchen ML, DiLuzio NR, Jacques P, MacVittie TJ. Soluble polyglycans enhance recovery from cobalt-60-induced hemopoietic injury. J Biol Response Mol. 1984; 3: 627-633.
Tohamy AA, El-Ghor AA, El-Nahas SM, Noshy MM. Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mutat Res. 2003; 541: 45-53.
Vetvicka V, Richter J, Kral V, Dobiásova Rajnohova L, Stiborova I, Pohorska J. Regulation of hematopoiesis in cancer patients: placebo – driven, double – blind clinical trials of β-glucan. J Tumor 2015; 1: 305–308.
Chan GC, Chan WK, Sze DM. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2: doi: 10.1186/1756-8722-2-25.
Chunjian Q, Yihua C, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JM, Yun J. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived. Blood 2011; 117: 6825–6836.
Vannucci L, Krizan J, Sima P, Stakheev D, Caja F, Rajsiglova L, Horak V, Saieh M. Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol. 2013; 43: 357–364.
Vetvicka V, Thorton BP, Wiemann JF, Ross GD. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J Immunol. 1997; 159: 599–605.
Nasrollahi Z, Mohammadi SR, Talaei F, Dinarvand R, Akbari H, Atyabi F. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: in vitro and in vivo study. J Controlled Rel. 2015; 202: 49-56.
Bergendiova K, Tibenska E, Majtan J. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol. 2011; 111: 2033–2040.
Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from Shiitake mushroom (Lentinus edodes). J Alt Compl Med. 2002; 8: 581-589.
Vetvicka V, Vetvickova J. 1,3-Glucan: Silver bullet or hot air? Open Glycoscience 2010; 3: 1-6.
Jamois F, Ferrières V, Guégan JP, Yvin JC, Plusquellec D, Vetvicka V. Glucan-like synthetic oligosaccharides: iterative synthesis of linear oligo-beta-(1,3)-glucans and immunostimulative effects. Glycobiology 2005; 15: 393-407.
Legentil L, Franck F, Ballet C, Trouvelot S, Daire X, Vetvicka V, Ferrieres V. Molecular interaction of β-(1-3)-glucans with their receptors. Molecules 2015; 20: 9745-9766.
Bohn JA, VeMiller JN. (1-3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Pol. 1995; 1: 3-14.
Di Renzo L, Yefenof E, Klein E. The function of human NK cells is enhanced by β-glucan, a ligand of CR3 (CD11b/CD18). Eur J Immunol. 1991; 21: 1755-1758.
Cheung NKV, Modak S, Vickers A, Knuckles B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunotherap. 2002; 51: 557-564.
Browse journals by subject